CD105 is also known as Endoglin and it modulates cellular response to TGF-β1, involved in vascular development and remodeling. It is a type I integral membrane homodimer protein with subunits of 90 kD found on vascular endothelial cells, bone marrow stromal cells, and hematopoietic stem/progenitor cells. CD105 is weakly expressed on stromal fibroblasts. It is also expressed on activated monocytes and tissue macrophages. Expression of CD105 is increased on activated endothelium in tissues undergoing angiogenesis, such as in tumors, or in cases of wound healing or dermal inflammation. CD105 is a component of the TGF-β receptor system in human umbilical vein endothelial cells and binds TGF-β1 and β3 with high affinity but does not bind to TGF-β2.
This product is being offered as part of our Beta Testing program. It has saporin activity confirmed, peptide sequences published/confirmed, and/or antibody binding specificity published/confirmed. It has not been characterized or reported in scientific literature. The researcher who first publishes data* will receive a $500 credit for use on ATS products.
*Data subject to review by the scientific team at ATS. See complete details here.
Anti-CD105-SAP eliminates cells expressing human CD105 (Endoglin). All other cells are left untouched.
To view protocol(s) for this and other products please visit: www.ATSbio.com/support/protocols